Your browser doesn't support javascript.
loading
Cost-effectiveness of colorectal cancer screening in Ukraine.
Melnitchouk, Nelya; Soeteman, Djøra I; Davids, Jennifer S; Fields, Adam; Cohen, Joshua; Noubary, Farzad; Lukashenko, Andrey; Kolesnik, Olena O; Freund, Karen M.
Afiliação
  • Melnitchouk N; 1Department of Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital/Harvard Medical School, 75 Francis St, Boston, MA 02115 USA.
  • Soeteman DI; 2Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA USA.
  • Davids JS; UMass Medical Center, Worcester, MA USA.
  • Fields A; 1Department of Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital/Harvard Medical School, 75 Francis St, Boston, MA 02115 USA.
  • Cohen J; Tufts Clinical and Translational Science Institute, Boston, MA USA.
  • Noubary F; Tufts Clinical and Translational Science Institute, Boston, MA USA.
  • Lukashenko A; National Cancer Institute, Kiev, Ukraine.
  • Kolesnik OO; National Cancer Institute, Kiev, Ukraine.
  • Freund KM; 6Tufts Medical Center and Tufts University School of Medicine Boston, Boston, MA USA.
Cost Eff Resour Alloc ; 16: 20, 2018.
Article em En | MEDLINE | ID: mdl-29977160
ABSTRACT

BACKGROUND:

Colorectal cancer is one of the most common cancers worldwide and is associated with high mortality when detected at a later stage. There is a paucity of studies from low and middle income countries to support the cost-effectiveness of colorectal cancer screening. We aim to analyze the cost-effectiveness of colorectal cancer screening compared to no screening in Ukraine, a lower-middle income country.

METHODS:

We developed a deterministic Markov cohort model to assess the cost-effectiveness of three colorectal cancer screening strategies [fecal occult blood test (FOBT) every year, flexible sigmoidoscopy with FOBT every 5 years, and colonoscopy every 10 years] compared to no screening. We modeled outcomes in terms of cost per quality-adjusted life-years (QALYs) over a lifetime time horizon. We performed sensitivity analyses on treatment adherence, test characteristics and costs. Analyses were conducted from the perspective of the Ministry of Health of Ukraine.

RESULTS:

The base-case lifetime cost-effectiveness analysis showed that all three screening strategies were cost saving compared to no screening, and among the three strategies, colonoscopy every 10 years was the dominant strategy compared to no screening with standard adherence to treatment. When decreased adherence to treatment was modeled, colonoscopy every 10 years was the most cost-effective strategy with an incremental cost-effectiveness ratio of $843 per QALY compared with no screening.

CONCLUSION:

Our findings indicate that colorectal cancer screening can save money and improve health compared to no screening in Ukraine. Colonoscopy every 10 years is superior to the other screening modalities evaluated in this study. This knowledge can be used to concentrate efforts on developing a national screening program in Ukraine.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article